2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 309

Increasing Capacity and Reducing Costs of Rituximab Administration

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 40

Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 477

Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 306

Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 19

Inhibition of IkB Kinase-IKK Complex of Canonical NF-κB Pathway in Antiphospholipid Antibody-Mediated Endothelial Cell Activation

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 507

Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 122

Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 71

Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 547

Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 753

Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 233

Intensive CBT Is Effective in the Treatment of Significant Functional Impairment and Psychological Distress Found in Fibromyalgia: But Can We Improve Depressive Symptoms?

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 5

Interferon Kappa Promotes the Development of Psoriasis

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 93

Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 777

Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 758

Interleukin-6 May Predict Disease Relapse During Long-term Follow-up in Takayasu’s Arteritis in a Han Chinese Population

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].